Cytopheresis cartridges and use thereof
AssigneeSeaStar Medical, Inc.
InventorsH. David Humes, Deborah A. Buffington, Christopher J. Pino
Life of this patent
Estimating the term…
Abstract
The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets.
Claims19
A method for processing an activated leukocyte, an activated platelet, or both an activated leukocyte and an activated platelet contained within a body fluid, the method comprising:
- (a) providing a cartridge comprising
- (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port;
- and
- (ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte and/or an activated platelet if present in a body fluid entering the housing via the fluid inlet port, wherein the cartridge has an SA/IV ratio ranging from greater than 150 cm−1 to 800 cm−1;
- (b) introducing blood from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support;
- and
- (c) treating the leukocyte and/or platelet sequestered in step (b) to inhibit release of a pro-inflammatory substance or to deactivate the leukocyte and/or the platelet.
A method for treating a subject having or at risk of developing an inflammatory condition, the method comprising:
- (a) providing a cartridge comprising
- (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port;
- and
- (ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte, if present in a body fluid entering the housing via the fluid inlet port, wherein the cartridge has an SA/IV ratio ranging from greater than 150 cm−1 to 800 cm−1;
- (b) introducing a body fluid blood from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support;
- and
- (c) treating the leukocyte and/or platelet sequestered in step (b) with a calcium chelator to inhibit the release of a pro-inflammatory substance from or to deactivate the leukocyte or platelet thereby to reduce the risk of developing inflammation associated with the inflammatory condition or to alleviate inflammation associated with the inflammatory condition.
Dependencies are inferred from the claim text.